Segment and Geographical Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions		3 Months Ended								12 Months Ended
		Dec. 27, 2019	Sep. 27, 2019	Jun. 28, 2019	Mar. 29, 2019	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 27, 2019	Dec. 28, 2018	Dec. 29, 2017
Segment Reporting Information [Line Items]
Assets		$ 10,338.9				$ 10,877.3				$ 10,338.9	$ 10,877.3
Net sales		$ 804.9	$ 743.7	$ 823.3	$ 790.6	$ 834.9	$ 799.9	$ 825.5	$ 755.3	3,162.5	3,215.6	$ 3,221.6
Operating income (loss)										(1,822.2)	(3,720.9)	492.9
Intangible asset amortization										(853.4)	(740.2)	(694.5)
Restructuring and related charges, net										1.7	(108.2)	(36.4)
Non-restructuring impairment										388.0	3,893.1	63.7
Opioid-related litigation settlement charge										1,643.4	0.0	0.0
Depreciation and amortization										951.1	852.1	808.3
Restructuring and related costs, accelerated depreciation										0.0	5.2	5.2
Specialty Brands [Member]
Segment Reporting Information [Line Items]
Restructuring and related charges, net										13.7	(54.6)	(25.4)
Specialty Generics [Member]
Segment Reporting Information [Line Items]
Restructuring and related charges, net										(10.0)	(5.3)	(7.7)
Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)										1,282.6	1,182.4	1,412.7
Operating Segments | Specialty Brands [Member]
Segment Reporting Information [Line Items]
Net sales										2,423.8	2,496.7	2,352.0
Operating income (loss)										1,174.5	1,093.1	1,146.3
Depreciation and amortization										862.4	762.5	712.0
Operating Segments | Specialty Generics [Member]
Segment Reporting Information [Line Items]
Net sales										738.7	718.9	869.6
Operating income (loss)										108.1	89.3	266.4
Depreciation and amortization										88.7	89.6	96.3
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Corporate and allocated expenses	[1]									(137.8)	(155.8)	(125.2)
Intangible asset amortization										(853.4)	(740.2)	(694.5)
Restructuring and related charges, net	[2]									1.7	(108.2)	(36.4)
Non-restructuring impairment										(388.0)	(3,893.1)	(63.7)
Separation costs	[3]									63.9	6.0	0.0
R&D upfront payment	[4]									(20.0)	0.0	0.0
Opioid-related litigation settlement charge	[5]									$ (1,643.4)	$ 0.0	$ 0.0

[1] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

[2] Includes restructuring-related accelerated depreciation.

[3] Represents costs incurred related to the separation of the Company's Specialty Generics segment, inclusive of costs related to the suspended spin-off of that business and rebranding costs associated with the Specialty Brands ongoing transformation, all of which are included in SG&A.

[4] Represents R&D expense incurred related to an upfront payment made to Silence in connection with the license and collaboration agreement entered into in July 2019. See Note 6 for further information.

[5] Subsequent to December 27, 2019, the Company announced an agreement in principle on the terms of a global settlement of all opioid-related claims against the Company and its subsidiaries. See Note 24 for further information.